Topas Therapeutics GmbH

16 articles about Topas Therapeutics GmbH

• Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer

  5/25/2023

  Topas Therapeutics announced the launch of a Phase 2a clinical study evaluating the safety, tolerability and pharmacodynamics of TPM502 in patients with celiac disease.

• 

  BioSpace Movers & Shakers, Feb. 18

  2/18/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

  2/15/2022

  Topas Therapeutics GmbH, a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, announced the appointment of Cristina de Min, M.D., as Chief Medical Officer.

• Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

  7/29/2021

  Topas Therapeutics GmbH, a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, announced that the Company has successfully extended its Series B round with an additional €18 million raised, bringing the total for this financing to €40 million.

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

  10/19/2020

  Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, announced the successful closing of a €22 million Series B financing round.

• Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

  10/19/2020

  Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer.

• Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

  12/19/2019

  • First program from the Topas platform to enter clinical testing • TPM203 is one of several proprietary programs being developed by Topas • Pemphigus vulgaris is an orphan indication that currently has no cure

• Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

  12/18/2019

  Topas Therapeutics GmbH announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris, an orphan autoimmune disease.

• Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

  3/20/2019

  Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, announced that the Company will participate at several conferences this spring.

• Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

  9/27/2018

  Topas Therapeutics GmbH today announced that the Company will participate at the following conferences this fall

• Topas Therapeutics Extends Its Series A to EUR 18 Million (USD 21 Million) With Boehringer Ingelheim Venture Fund

  11/2/2017

  BIVF will provide Topas with EUR 4 million (USD 5 million) to accelerate the Company's preparation and execution of clinical trials for autoimmune programs derived from its platform.

• Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., As Chief Development Officer and Chief Medical Officer

  10/26/2017

  Topas Therapeutics GmbH (Topas) announced the appointment of Rupert Sandbrink, M.D., Ph.D., to the newly created position of Chief Development Officer and Chief Medical Officer.

• Topas Therapeutics GmbH Signs Multi-Year Research And Option Agreement With Eli Lilly Focused On Immune Tolerance

  8/22/2017

• Paul Sekhri Joins Topas Therapeutics GmbH As Chairman Of The Board

  4/4/2017

• Evotec Technologies GmbH Spins off Auto-Immune Biz as 'Topas Therapeutics GmbH'

  3/22/2016